J&J CFO Caruso Breaks Down the Earnings Numbers

The transcript features an interview with Johnson & Johnson's CFO, Dominic Caruso, discussing the company's strong start to the year, driven by robust pharmaceutical sales and a promising product pipeline. The conversation covers the potential impact of biosimilars on Remicade, the company's capital allocation strategy, including dividends and share buybacks, and the performance of the consumer business in emerging markets. Caruso also addresses the topic of corporate tax inversions, emphasizing the need for tax system reform to encourage innovation.

What factors contributed to the strong performance of the pharmaceutical sales mentioned in the text?

How does the company plan to address the potential threat of biosimilars to their product Remicade?

What is the company's strategy regarding capital allocation and shareholder returns?

What opportunities does the consumer business see in emerging markets despite economic slowdowns?

What are the key points discussed regarding the topic of corporate tax system revisions?